Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from SSY Group ( (HK:2005) ).
SSY Group Limited has obtained approval from China’s National Medical Products Administration for its Propranolol Hydrochloride to be registered as a bulk drug for use in market preparations. The beta-blocker product targets key cardiovascular indications including post-myocardial infarction mortality reduction, hypertension, exertional angina and various supraventricular and ventricular arrhythmias.
The approval broadens SSY Group’s cardiovascular portfolio and enhances its role as a supplier to China’s pharmaceutical formulations market. The new bulk drug qualification is expected to strengthen the group’s product mix in high-demand chronic disease segments, potentially supporting more stable revenue streams from hospital and prescription channels.
The most recent analyst rating on (HK:2005) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited is a Hong Kong-listed pharmaceutical group engaged in the development and production of drug products for the Chinese healthcare market. The company focuses on supplying bulk drugs and related preparations, serving therapeutic areas such as cardiovascular disease and other conditions treated in hospitals nationwide.
Average Trading Volume: 4,820,446
Technical Sentiment Signal: Sell
Current Market Cap: HK$8.94B
Learn more about 2005 stock on TipRanks’ Stock Analysis page.